DelveInsight's 'Geographic Atrophy (GA) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Geographic Atrophy (GA) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030
Geographic Atrophy (GA) Understanding
Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration also called age-related macular degeneration (AMD or ARMD) is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: "dry" and "wet". According to the "American Macular Degeneration Foundation," approximately 85-90% of the cases of macular degeneration are the "dry" (atrophic) type.
GA is a progressive, irreversible and blinding disease that tends to affect both eyes. Nearly two-thirds geographic atrophy cases are reported in the people aged 80 years and above. GA is responsible for ~20% of all cases of legal blindness in the US and 26% of cases in the UK.
GA is characterized by one or more distinct dark patches on the retina, with corresponding areas of reduced vision or 'blind spots'. These dark patches represent the death of different cell types in the retina, including the light-sensitive photoreceptors.
The development of imaging technologies has contributed to the understanding of the genesis and pathophysiological mechanisms of GA secondary to AMD. At present, to distinguish GA from other forms of dry AMD, color fundus photography and biomicroscopy FA examination are used. In addition to this, modern in vivo imaging technology, such as spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF) allows for non-invasive and rapid quantitative morphological assessment of GA in the clinical setting also being used for GA.
Geographic Atrophy (GA) Epidemiology Perspective by DelveInsight
The GA epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The GA epidemiology data are studied through GA possible division to give a better understanding of the Disease scenario in the 7MM.
The disease epidemiology covered in the report provides historical as well as forecasted GA epidemiology [segmented as Total Prevalent Cases of GA, Total Diagnosed Cases of GA, Total Diagnosed cases of GA by Age Distribution, Total Geographic Atrophy Cases by Visual Impairment, and Total Treated Cases of GA] scenario of GA in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.
Geographic Atrophy (GA) Detailed Epidemiology Segmentation
- The total prevalent cases of GA in the 7MM were found to be 2,726,453 in 2017 which is expected to grow during the study period, i.e., 2017-2030.
- In the 7MM, the total diagnosed cases of GA were 2,516,401 cases in 2017.
- The highest number of diagnosed prevalent cases was observed in the United States. On the other hand, in EU-5 countries, the highest number of diagnosed prevalent cases of GA was found in the UK with 282,917cases in 2017, followed by France and Germany. Spain accounted for the least number of diagnosed prevalent cases in the 7MM. Also, Japan accounted for 173,465 diagnosed prevalent cases in 2017.
- In age-specific cases of GA, in 2017, the most number of cases (i.e. nearly two-thirds) was seen in patients of age ≥80 years, followed by the age-group of 75-79 years and 70-74 years.
- In total GA cases by visual impairment, most of the cases (i.e. around 50%) were moderate to severe impairment followed by mild. Patients having moderate to severe visual impairment were accounted for 1,258,200 cases in 2017.
Scope of the Report
- The Geographic Atrophy (GA) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Geographic Atrophy (GA) Epidemiology Report and Model provide an overview of the risk factors and global trends of Geographic Atrophy (GA) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Geographic Atrophy (GA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Geographic Atrophy (GA)
- The report provides the segmentation of the Geographic Atrophy (GA) epidemiology
- 11-Year Forecast of Geographic Atrophy (GA) epidemiology
- Total Cases of Geographic Atrophy (GA)
- Total Cases of Geographic Atrophy (GA) according to segmentation
- Diagnosed cases of Geographic Atrophy (GA)
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered:
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Geographic Atrophy (GA)?
- What are the key findings pertaining to the Geographic Atrophy (GA) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
- What would be the total number of patients of Geographic Atrophy (GA) across the 7MM during the forecast period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
- What is the disease risk, burden and unmet needs of the Geographic Atrophy (GA)?
- What are the currently available treatments of Geographic Atrophy (GA)?
Reasons to buy:
- The Geographic Atrophy (GA) Epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Geographic Atrophy (GA) market
- Quantify patient populations in the global Geographic Atrophy (GA) market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Geographic Atrophy (GA) therapeutics in each of the markets covered
- Understand the magnitude of Geographic Atrophy (GA) population by its epidemiology
- The Geographic Atrophy (GA) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population